Evidence map›Paper›PMID 31700039›Full record

ArticleScientific reports2019

The beneficial effects of a muscarinic agonist on pancreatic β-cells.

Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Yasuo Terauchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. GABA signalling in human pancreatic islets.Frontiers in endocrinology · 2023
    Review
  4. Review
  5. Quercetin prevents insulin dysfunction in hypertensive animals.Journal of diabetes and metabolic disorders · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuzuru ItoDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Mitsuyo KajiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Eri SakamotoDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan. terauchi@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-8872-3697
Yokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The brain and nervous system play an important role in pancreatic β-cell function. This study investigated the role of muscarinic agonists or acetylcholine, which is the major neurotransmitter in the vagal nerve, in regulating pancreatic β-cell mass and glucose homeostasis. Administration of the muscarinic agonist bethanechol increased insulin secretion and improved glucose tolerance in insulin-receptor substrate 2 (IRS2)-knockout (IRS-2

Indexed as

Administration, OralAnimalsBethanecholCell LineCell ProliferationGlucagon-Like Peptide 1Insulin Receptor Substrate ProteinsInsulin-Secreting CellsMiceMice, KnockoutMuscarinic AgonistsProto-Oncogene Proteins c-aktSignal TransductionBethanecholGlucagon-Like Peptide 1Insulin Receptor Substrate ProteinsIrs2 protein, mouseMuscarinic AgonistsProto-Oncogene Proteins c-akt

Identifiers

PMID31700039
PMCPMC6838462
OpenAlexW2983655081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.